Parataxis Holdings LLC has agreed to invest nearly $18.3 million (KRW 25 billion) in South Korea’s Bridge Biotherapeutics, gaining a controlling stake and rebranding the company as Parataxis Korea. Once finalized, the deal will establish the first Bitcoin-native treasury platform in the South Korean public markets, leveraging the digital asset expertise of Parataxis Capital. Leadership […]
Read the full article here
